DEREK KABASAWA: Open Payments
NPI 1710611884 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,910 in 113 payments from 15 companies in 2025. Trend: 2023 $1,613 · 2024 $1,356 · 2025 $1,910
Food & beverage: $1,910
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $296 |
| Teva Pharmaceuticals USA, Inc. | 20 | $293 |
| Vanda Pharmaceuticals Inc. | 14 | $240 |
| Alkermes, Inc. | 11 | $209 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $198 |
| Janssen Pharmaceuticals, Inc | 11 | $152 |
| Neurocrine BioSciences, Inc. | 8 | $146 |
| Axsome Therapeutics, Inc. | 4 | $70 |
| Supernus Pharmaceuticals, Inc. | 4 | $65 |
| Noven Therapeutics, LLC | 4 | $61 |
Products named: REXULTI, FANAPT, CAPLYTA, UZEDY, ARISTADA, INGREZZA, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across OK — which companies pay providers there.
